Latest Hotspot

TransCode Therapeutics Reports Promising Initial Human Trial Results for New Therapy, TTX-MC138

7 June 2024
3 min read

TransCode Therapeutics, Inc., an RNA oncology firm dedicated to revolutionizing cancer treatment with RNA-based therapies, has released early findings from its Phase 0 clinical trial involving radiolabeled TTX-MC138, indicating potential anti-tumor effects.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

New findings from a patient administered this study's treatment show that a small dose of radiolabeled TTX-MC138 led to a notable inhibition of the molecular target, miRNA-10b, in the patient’s bloodstream. Specifically, post-injection, the miR-10b levels in the patient's blood significantly dropped compared to pre-administration levels of radiolabeled TTX-MC138, achieving a 66% reduction 24 hours after dosing. 

“These findings are significant because in multiple animal studies, the inhibition of miRNA-10b by TTX-MC138 resulted in complete regression of metastatic disease,” stated Zdravka Medarova, PhD, Chief Scientific Officer at TransCode. The data align with TransCode’s position that TTX-MC138’s clinical development has the potential to benefit patients with metastatic cancer.

Moreover, the research quantified the delivery amount of the drug candidate to metastatic sites, providing additional proof that TTX-MC138 accumulates in metastatic tumors. The increased radioactive lesion-to-blood ratios indicate that circulating TTX-MC138 is preferentially taken up by cancerous tissues.

“These new findings suggest TTX-MC138 not only inhibits the miRNA-10b target but is pharmacodynamically active at a single microdose in the patient’s plasma, supporting the continued clinical development of TTX-MC138 for treating various metastatic cancers in the upcoming Phase 1 clinical study. This could imply a much wider therapeutic range than previously anticipated,” said Dr. Daniel Vlock, TransCode’s Chief Medical Officer.

TTX-MC138, an antisense oligonucleotide drug developed by TransCode Therapeutics, Inc., targets miR-10b and is being developed to treat a broad spectrum of therapeutic areas, including neoplasms, nervous system diseases, digestive system disorders, endocrinology and metabolic diseases, skin and musculoskeletal diseases, urogenital diseases, and respiratory diseases. The active indications for TTX-MC138 include advanced malignant solid neoplasms, breast cancer, colonic cancer, glioblastoma, ovarian cancer, pancreatic cancer, osteosarcoma, and small cell lung cancer.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面

描述已自动生成

According to the data provided by the Synapse Database, As of June 6, 2024, there are 4 investigational drugs for the miR-10b targets, including 8 indications, 5 R&D institutions involved, with related clinical trials reaching 1, and as many as 1016 patents.

TTX-MC-138 has reached the highest global phase of Phase 1/2 in its development. Additionally, the drug has been designated as an orphan drug, indicating its intended use in the treatment of rare diseases or conditions.The development of TTX-MC-138 as an antisense oligonucleotide drug targeting miR-10b represents a novel approach in the field of biomedicine. The drug's broad therapeutic areas and active indications suggest its potential to address unmet medical needs across various disease categories.

图形用户界面, 文本

描述已自动生成

Biohaven Administers First Dose of New Trop-2 Targeting ADC BHV-1510 to Cancer Patient
Latest Hotspot
3 min read
Biohaven Administers First Dose of New Trop-2 Targeting ADC BHV-1510 to Cancer Patient
7 June 2024
Biohaven administers initial dose of new Trop-2 targeting ADC BHV-1510 to patient with advanced or metastatic epithelial cancers.
Read →
FDA Approves Full-Life Technologies' IND Application for 225Ac-FL-020 in Treating Metastatic Castration-Resistant Prostate Cancer
Latest Hotspot
3 min read
FDA Approves Full-Life Technologies' IND Application for 225Ac-FL-020 in Treating Metastatic Castration-Resistant Prostate Cancer
7 June 2024
Full-Life Technologies Gets FDA Nod for IND Application of 225Ac-FL-020 in Treating Metastatic Castration-Resistant Prostate Cancer.
Read →
Zanidatamab Receives Priority Review for HER2-Positive Advanced Biliary Tract Cancer
Latest Hotspot
3 min read
Zanidatamab Receives Priority Review for HER2-Positive Advanced Biliary Tract Cancer
7 June 2024
Jazz Pharmaceuticals plc has reported that the Biologics License Application for zanidatamab, has been accepted and given Priority Review status by the U.S. Food and Drug Administration.
Read →
Telix Announces Positive rPFS Results from ProstACT SELECT Trial for Prostate Cancer Therapy TLX591
Latest Hotspot
3 min read
Telix Announces Positive rPFS Results from ProstACT SELECT Trial for Prostate Cancer Therapy TLX591
6 June 2024
Telix Reports Encouraging rPFS Results from TLX591 rADC Therapy Candidate ProstACT SELECT Trial for Prostate Cancer.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.